Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter. The Fund performed roughly in line with the Benchmark, during a challenging ...

The Company’s 2025 financial guidance reflects its evolution to a fully integrated commercial-stage biotechnology company independently ...

Reports Q4 revenue $$227.00M, consensus $140.95M.”With the recent launch of our first independent medicine, TRYNGOLZA for familial ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

The increasing prevalence of chronic conditions like cardiovascular disease is driving the demand for transmucosal drugs. Key factors contributing to the transmucosal drugs market's growth from ...

Innovative Chronic Pain Treatment Receives IP Protection in India's $55 Billion Pharmaceutical Market HERZLIYA, Israel and CALGARY, AB, Feb. 18, 2025 /PRNewswire/ -- Innocan Pharma ...

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the ...

Discover key insights from Basilea Pharmaceutica AG's Q4 2024 earnings call. Learn about robust revenue growth, FDA approvals, and pipeline advancements.

Axsome Therapeutics reports 66% Q4 revenue growth, blockbuster potential for Auvelity, and robust pipeline progress with 3 NDA filings and key ...

Oncolytics Biotech® Inc. , a leading clinical-stage company specializing in immunotherapy for oncology, continues to make good progress in 2025 with key regulatory and clinical advancements, ...

VIVOZON Pharmaceutical announced that its non-opioid analgesic, UNAFRA Inj., was approved on December 12, 2024. (Active ...